Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts
Denosumab Biosimilars Impact Expected Later This Year
Gains from products besides Prolia and Xgeva will grow Amgen's 2025 sales after denosumab biosimilars puts pressure on total revenue (Shutterstock) 
